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Abstract
Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing preva-
lence has implications for the risk of diabetes, cardiovascular disease and also for Chronic Kidney Disease. A high body mass index is one 
of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a compensatory hyperfiltration occurs 
to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys 
and raise the risk of developing Chronic Kidney Disease in the long-term. The incidence of obesity-related glomerulopathy has increased 
ten-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including 
kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney 
disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.
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Resumen
La obesidad se ha convertido en una epidemia mundial, y se ha proyectado que su prevalencia se incrementará en un 40% en la próxima 
década. Esta creciente prevalencia supone implicaciones tanto para el riesgo de desarrollo de diabetes y enfermedades cardiovasculares 
como para el desarrollo de Enfermedad Renal Crónica. Un elevado índice de masa corporal es uno de los factores de riesgo más importantes 
para el desarrollo de Enfermedad Renal Crónica. En individuos afectados por la obesidad, tiene lugar una hiperfiltración compensatoria 
necesaria para alcanzar la alta demanda metabólica secundaria al aumento del peso corporal. El incremento de la presión intraglomerular 
puede generar daño renal y elevar el riesgo de desarrollar Enfermedad Renal Crónica a largo plazo. La incidencia de glomerulopatía asocia-
da a obesidad se ha incrementado 10 veces en los últimos años. Así mismo se ha demostrado que la obesidad es un factor de riesgo para el 
desarrollo de nefrolitiasis y un número de neoplasias, incluyendo cáncer renal. Este año, el Día Mundial del Riñón promueve la educación 
a cerca de las consecuencias nocivas de la obesidad y su asociación con la enfermedad renal, abogando por un estilo de vida saludable y la 
implementación de políticas públicas de salud que promuevan medidas preventivas alcanzables.
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Introduction
In 2014, over 600 million adults worldwide, 18 years and older, were obese. Obesity is a potent risk factor for the development of kid-
ney disease. It increases the risk of developing ma-
jor risk factors for Chronic Kidney Disease (CKD), 
like diabetes and hypertension, and it has a direct 
impact on the development of CKD and end-sta-
ge renal disease (ESRD). In individuals affected 
by obesity, a (likely) compensatory mechanism of 
hyperfiltration occurs to meet the heightened meta-
bolic demands of the increased body weight. The 
increase in intraglomerular pressure can damage 
the kidney structure and raise the risk of developing 
CKD in the long-term.
The good news is that obesity, as well as the re-
lated CKD, are largely preventable. Education and 
awareness of the risks of obesity and a healthy li-
festyle, including proper nutrition and exercise, can 
dramatically help in preventing obesity and kidney 
disease. This article reviews the association of obe-
sity with kidney disease on the occasion of the 2017 
World Kidney Day.
Epidemiology of obesity in adults and 
children
Over the last 3 decades, the prevalence of 
overweight and obese adults (BMI ≥25 kg/m2) 
worldwide has increased substantially.1 In the US, 
the age-adjusted prevalence of obesity in 2013-2014 
was 35% among men and 40.4% among women2. 
The problem of obesity also affects children. In the 
US in 2011-2014, the prevalence of obesity was 
17% and extreme obesity 5.8% among youth 2-19 
years of age. The rise in obesity prevalence is also 
a worldwide concern,3;4 as it is projected to grow by 
40% across the globe in the next decade. Low- and 
middle-income countries are now showing eviden-
ce of transitioning from normal weight to overwei-
ght and obesity as parts of Europe and the United 
States did decades ago5. This increasing prevalence 
of obesity has implications for cardiovascular di-
sease (CVD) and also for CKD. A high body mass 
index (BMI) is one of the strongest risk factors for 
new-onset CKD6;7. 
Definitions of obesity are most often based on 
BMI (i.e. weight [kilograms] divided by the square 
of his or her height [meters]). A BMI between 18.5 
and 25 kg/m2 is considered by the World Health 
Organization (WHO) to be normal weight, a BMI 
between 25 and 30 kg/m2 as overweight, and a BMI 
of >30 kg/m2 as obese. Although BMI is easy to cal-
culate, it is a poor estimate of fat mass distribution, 
as muscular individuals or those with more subcu-
taneous fat may have a BMI as high as individuals 
with larger intraabdominal (visceral) fat.  The latter 
type of high BMI is associated with substantially 
higher risk of metabolic and cardiovascular disease. 
Alternative parameters to more accurately capture 
visceral fat include waist circumference (WC) and a 
waist hip ratio (WHR) of >102 cm and 0.9, respec-
tively, for men and >88 cm and >0.8, respectively, 
for women. WHR has been shown to be superior 
to BMI for the correct classification of obesity in 
CKD.
Association of obesity with CKD and 
other renal complications
Numerous population based studies have 
shown an association between measures of obesity 
and both the development and the progression of 
CKD (Table 1). Higher BMI is associated with the 
presence8 and development9-11 of proteinuria in 
individuals without kidney disease. Furthermore, 
in numerous large population-based studies, higher 
BMI appears associated with the presence8;12 and 
development of low estimated GFR,9;10;13 with more 
rapid loss of estimated GFR over time,14 and with 
the incidence of ESRD15-18. Elevated BMI levels, 
class II obesity and above, have been associated 
with more rapid progression of CKD in patients 
with pre-existing CKD19. A few studies examining 
the association of abdominal obesity using WHR 
or WC with CKD, describe an association between 
higher girth and albuminuria20, decreased GFR8 or 
incident ESRD21 independent of BMI level.
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Table 1.
Studies examining the association of obesity with various measures of CKD
Study Patients Exposure Outcomes Results Comments
Prevention of 
Renal and Vascular 
End-Stage Disease 
(PREVEND) Study8




obese*), and central fat 
distribution (waist-hip 
ratio)




-Obese + central fat: higher risk of 
albuminuria
-Obese +/- central fat: higher risk 
of elevated GFR






20,828 patients from 26 
countries
BMI and waist 
circumference
Prevalence of 
albuminuria by dip 
stick
Higher waist circumference 








Visceral adipose tissue 
(VAT) and subcutaneous 
adipose tissue (SAT)
Prevalence of UACR 
>25 mg/g in women 
and >17 mg/g in men
VAT associated with albuminuria 







dwelling individuals with 
normal kidney function 
aged 28-40 years






Obesity (OR 1.9) and unhealthy 
diet (OR 2.0) associated with 
incident albuminuria





5,897 hypertensive adults Overweight and obese BMI* vs. normal BMI
Incident CKD (1+ or 
greater proteinuria on 
urinalysis and/or an 
eGFR <60 mL/min/1.73 
m2)
Both overweight (OR 1.21) and 
obesity (OR 1.40) associated with 
incident CKD




2,676 individuals free of 
CKD stage 3 High vs. normal BMI* 
-Incident CKD stage 3
-Incident proteinuria
-Higher BMI not associated with 
CKD3 after adjustments
-Higher BMI associated with 
increased odds of incident 
proteinuria




11,104 initially healthy 
men in US
-BMI quintiles
-Increase in BMI over 
time (vs. stable BMI)
Incident eGFR <60 mL/
min/1.73 m2
-Higher baseline BMI and increase 
in BMI over time both associated 






3,376,187 US veterans 
with baseline eGFR ≥60 
mL/min/1.73 m2
BMI categories from 
<20 to >50 kg/m2
Rapid decline in kidney 
function (negative 
eGFR slope of >5 mL/
min/1.73 m2)
BMI >30 kg/m2 associated with 
rapid loss of kidney function





926 Swedes with 
moderate/advanced CKD 
compared to 998 controls
BMI ≥25 vs. <25 kg/m2 CKD vs. no CKD Higher BMI associated with 3x higher risk of CKD
-Risk strongest in diabetics, 







males and females 




obesity) vs. normal 
BMI*
Incident ESRD
Overweight (HR 3.0) and obesity 
(HR 6.89) associated with higher 
risk of ESRD
Associations strongest for 
diabetic ESRD, but also 





74,986 Norwegian adults BMI categories* Incidence of ESRD or renal death
BMI >30 kg/m2 associated with 
worse outcomes
Associations not present in 





100,753 individuals >20 
years old BMI quartiles Incidence of ESRD
Higher BMI associated with 
increased risk of ESRD in men, but 
not in women
Average BMI lower in Japan 





453,946 US veterans with 
baseline eGFR<60 ml/min 
per 1.73 m2
BMI categories from 
<20 to >50 kg/m2
-Incidence of ESRD
-Doubling of serum 
creatinine
-Slopes of eGFR
Moderate and severe obesity 
associated with worse renal 
outcomes
Associations present but weaker 




320,252 adults with and 
without baseline CKD
Overweight, class I, II 
and extreme obesity; vs. 
normal BMI*
Incidence of ESRD Linearly higher risk of ESRD with higher BMI categories
Associations remained present 
after adjustment for DM, 
hypertension and baseline CKD
REGARDS (Reasons 
for Geographic and 
Racial Differences in 
Stroke) Study21 
30,239 individuals Elevated waist circumference or BMI Incidence of ESRD
BMI above normal not associated 
with ESRD after adjustment for 
waist circumference
-Higher waist circumference 
associated with ESRD
Association of waist 
circumference with ESRD 
became on-significant after 
adjustment for comorbidities and 
baseline eGFR and proteinuria
*Normal weight: BMI 18.5 to 24.9 kg/m2; overweight: BMI 25.0 to 29.9 kg/m2; class I obesity: BMI 30.0 to 34.9 kg/m2; class II obesity: BMI 35.0 to 39.9 kg/m2; class III 
obesity: BMI ≥40 kg/m2
BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; HR, hazard ratio; OR, 
odds ratio; UACR, urine albumin-creatinine ratio.
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Higher visceral adipose tissue measured by com-
puted tomography has been associated with a higher 
prevalence of albuminuria in men22. The observa-
tion of a BMI-independent association between ab-
dominal obesity and poorer renal outcomes is also 
described in relationship with mortality in patients 
with ESRD23 and kidney transplant24, and suggests 
a direct role of visceral adiposity. In general, the 
associations between obesity and poorer renal out-
comes persist even after adjustments for possible 
mediators of obesity’s cardiovascular and metabo-
lic effects, such as high blood pressure and diabetes 
mellitus, suggesting that obesity may affect kidney 
function through mechanisms in part unrelated to 
these complications (vide infra). 
The deleterious effect of obesity on the kidneys 
extends to other complications such as nephrolithia-
sis and kidney malignancies. Higher BMI is asso-
ciated with an increased prevalence25 and inciden-
ce26;27 of nephrolithiasis. Furthermore, weight gain 
over time, and higher baseline WC were also as-
sociated with higher incidence of nephrolithiasis27. 
Obesity is associated with various types of malig-
nancies, particularly cancers of the kidneys. In a 
population-based study of 5.24 million individuals 
from the UK, a 5 kg/m2 higher BMI was associated 
with a 25% higher risk of kidney cancers, with 10% 
of all kidney cancers attributable to excess weight28. 
Another large analysis examining the global burden 
of obesity on malignancies estimated that 17% and 
26% of all kidney cancers in men and women, res-
pectively, were attributable to excess weight29. The 
association between obesity and kidney cancers 
was consistent in both men and women, and across 
populations from different parts of the world in a 
meta-analysis that included data from 221 studies 
(of which 17 examined kidney cancers)30. Among 
the cancers examined in this meta-analysis, kidney 
cancers had the third highest risk associated with 
obesity (relative risk per 5 kg/m2 higher BMI: 1.24, 
95%CI 1.20-1.28, p<0.0001)30.
Mechanisms of action underlying the 
renal effects of obesity
Obesity results in complex metabolic 
abnormalities which have wide-ranging effects on 
diseases affecting the kidneys. The exact mechanisms 
whereby obesity may worsen or cause CKD remain 
unclear. The fact that most obese individuals never 
develop CKD, and the distinction of up to as many 
as 25% of obese individuals as “metabolically 
healthy” suggests that increased weight alone is 
not sufficient to induce kidney damage31. Some of 
the deleterious renal consequences of obesity may 
be mediated by downstream comorbid conditions 
such as diabetes mellitus or hypertension, but there 
are also effects of adiposity which could impact 
the kidneys directly, induced by the endocrine 
activity of the adipose tissue via production of 
(among others) adiponectin 32, leptin33 and resistin34 
(Figure 1). These include the development of 
inflammation35, oxidative stress36, abnormal lipid 
metabolism37, activation of the renin-angiotensin-
aldosterone system38, and increased production of 
insulin and insulin resistance39;40.
Figure 1. Putative mechanisms of action whereby obesity 
causes chronic kidney disease.
Obesity and kidney disease: hidden consequences of the epidemic
Rev. Colomb. Nefrol. 2017;4(1): 112 - 121. http://www.revistanefrologia.org 
116
These various effects result in specific patholo-
gic changes in the kidneys41 which could underlie 
the higher risk of CKD seen in observational stu-
dies. These include ectopic lipid accumulation42 and 
increased deposition of renal sinus fat43;44, the de-
velopment of glomerular hypertension and increa-
sed glomerular permeability caused by hyperfiltra-
tion-related glomerular filtration barrier injury45, 
and ultimately the development of glomerulome-
galy46, and focal or segmental glomerulosclerosis41 
(Figure 2). The incidence of the so-called obesi-
ty-related glomerulopathy (ORG) has increased 
ten-fold between 1986 and 200041. Importantly, 
ORG often presents along with pathophysiologic 
processes related to other conditions or advanced 
age, conspiring to result in more accentuated kid-
ney damage in patients with high blood pressure47 
or in the elderly14,39. 
tubular Na-H exchanger52 and ammoniagenesis53, 
and the promotion of an acidic milieu54. Compli-
cating the picture is the fact that some weight loss 
therapies result in a worsening, rather than an im-
provement in the risk for kidney stone formation; 
e.g. gastric surgery can lead to a substantial increase 
in enteral oxalate absorption and enhanced risk of 
nephrolithiasis55. 
The mechanisms behind the increased risk of 
kidney cancers observed in obese individuals are 
less well characterized. Insulin resistance, and the 
consequent chronic hyperinsulinemia and increa-
sed production of insulin-like growth factor 1 and 
numerous complex secondary humoral effects may 
exert stimulating effects on the growth of various 
types of tumor cells56. More recently, the endocrine 
functions of adipose tissue57, its effects on immuni-
ty58, and the generation of an inflammatory milieu 
with complex effects on cancers59;60 have emerged 
as additional explanations. 
Obesity in patients with advanced kid-
ney disease: The need for a nuanced 
approach
Considering the above evidence about the 
overwhelmingly deleterious effects of obesity on 
various disease processes, it is seemingly counte-
rintuitive that obesity has been consistently asso-
ciated with lower mortality rates in patients with 
advanced CKD19,61 and ESRD62-63. Similar “para-
doxical” associations have also been described in 
other populations, such as in patients with con-
gestive heart failure64, chronic obstructive pulmo-
nary disease65, rheumatoid arthritis66, and even in 
old individuals67. It is possible that the seemingly 
protective effect of a high BMI is the result of the 
imperfection of BMI as a measure of obesity, as it 
does not differentiate the effects of adiposity from 
those of higher non-adipose tissue. Indeed, studies 
that separated the effects of a higher waist circum-
ference from those of higher BMI showed a reversal 
of the inverse association with mortality23-24. Higher 
muscle mass has also been shown to explain at least 
Figure 2. Obesity-related perihilar focal segmental 
glomerulosclerosis on a background of glomerulomegaly. 
Periodic Acid-Schiff stain, original magnification 400x.
Obesity is associated with a number of risk fac-
tors contributing to the higher incidence and pre-
valence of nephrolithiasis. Higher body weight 
is associated with lower urine pH48 and increased 
urinary oxalate49, uric acid, sodium and phosphate 
excretion50 Diets richer in protein and sodium may 
lead to a more acidic urine and decrease in urinary 
citrate, also contributing to kidney stone risk. The 
insulin resistance characteristic of obesity may also 
predispose to nephrolithiasis51 through its impact on 
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some of the positive effects attributed to elevated 
BMI63-68. However, there is also evidence to sug-
gest that higher adiposity, especially subcutaneous 
(non-visceral) fat, may also be associated with be-
tter outcomes in ESRD patients62. Such benefits 
may indeed be present in patients who have very 
low short term life expectancy, such as most ESRD 
patients69. Indeed, some studies that examined the 
association of BMI with time-dependent survival 
in ESRD have shown a marked contrast between 
protective short term effects vs. deleterious lon-
ger term effects of higher BMI70. There are several 
putative short term benefits that higher body mass 
could portend, especially to sicker individuals. The-
se include a benefit from the better nutritional sta-
tus typically seen in obese individuals, and which 
provides better protein and energy reserves in the 
face of acute illness, and a higher muscle mass with 
enhanced antioxidant capacity63 and lower circula-
ting actin and higher plasma gelsolin levels71, which 
are associated with better outcomes. Other hypothe-
tically beneficial characteristics of obesity include 
a more stable hemodynamic status with mitigation 
of stress responses and heightened sympathetic and 
renin-angiotensin activity72; increased production 
of adiponectines73 and soluble tumor necrosis factor 
alfa receptors74 by adipose tissue neutralizing the 
adverse effects of tumor necrosis factor alfa; en-
hanced binding of circulating endotoxins75 by the 
characteristically higher cholesterol levels seen in 
obesity; and sequestration of uremic toxins by adi-
pose tissue76.
Potential interventions for management 
of obesity
Obesity engenders kidney injury via direct me-
chanisms through deranged synthesis of various 
adipose tissue cytokines with nephrotoxic poten-
tial, as well as indirectly by triggering diabetes and 
hypertension, i.e. two conditions that rank among 
the strongest risk factors for CKD. Perhaps due to 
the survival advantage of obesity in CKD, the pre-
valence of end stage kidney disease is on the rise 
both in the USA77 and in Europe78. Strategies for 
controlling the obesity related CKD epidemic at 
population level and for countering the evolution 
of CKD toward kidney failure in obese patients re-
present the most tantalizing task that today’s health 
planners, health managers and nephrologists face.
Countering CKD at population level
Calls for public health interventions in the com-
munity to prevent and treat CKD at an early stage 
have been made by major renal associations, inclu-
ding the International Society of Nephrology (ISN), 
International Federation of the Kidney Foundation 
(IFKF), the European renal association (ERA-ED-
TA) and various national societies. In the USA, 
Healthy People 2020, a program that sets 10-year 
health targets for health promotion and prevention 
goals, focuses both on CKD and obesity. Surveys 
to detect obese patients, particularly those with a 
high risk of CKD (e.g. hypertensive and/or diabe-
tic obese people) and those receiving suboptimal 
care to inform these patients of the potential risk for 
CKD they are exposed to, is the first step towards 
developing public health interventions. Acquiring 
evidence that current interventions to reduce CKD 
risk in the obese are efficacious and deployable, is 
an urgent priority to set goals and means for risk 
modification. Appropriate documentation of exis-
ting knowledge distilling the risk and the benefits 
of primary and secondary prevention interventions 
in obese people, and new trials in this population to 
fill knowledge gaps (see below) are needed. Finally, 
surveillance programs that monitor progress on the 
detection of at-risk individuals and the effectiveness 
of prevention programs being deployed79 constitute 
the third, fundamental element for establishing effi-
cacious CKD prevention plans at population level.
A successful surveillance system for CKD has 
already been implemented in some places such as 
the United Kingdom (UK).80 A campaign to dis-
seminate and apply K-DOQI CKD guidelines in 
primary care within the UK National Health Servi-
ce was launched. This progressively increased the 
Obesity and kidney disease: hidden consequences of the epidemic
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adoption of K-DOQI guidelines and, also thanks 
to specific incentives for UK general physicians to 
detect CKD, led to an impressive improvement in 
the detection and care of CKD, i.e. better control of 
hypertension and increased use of angiotensin-con-
verting enzyme and angiotensin receptor blockers80. 
This system may serve as a platform to improve the 
prevention of obesity-related CKD. Campaigns ai-
ming at reducing the obesity burden are now at cen-
ter stage worldwide and are strongly recommended 
by the WHO and it is expected that these campaigns 
will reduce the incidence of obesity-related compli-
cations, including CKD. However obesity-related 
goals in obese CKD patients remain vaguely formu-
lated, largely because of the paucity of high-level 
evidence intervention studies to modify obesity in 
CKD patients81.
Prevention of CKD progression in obese people 
with CKD
Observational studies in metabolically healthy 
obese subjects show that the obese phenotype unas-
sociated with metabolic abnormalities per se pre-
dicts a higher risk for incident CKD82 suggesting 
that obesity per se may engender renal dysfunc-
tion and kidney damage even without diabetes or 
hypertension (vide supra). In overweight or obese 
diabetic patients, a lifestyle intervention including 
caloric restriction and increased physical activity 
compared with a standard follow up based on edu-
cation and support to sustain diabetes treatment re-
duced the risk for incident CKD by 30%, althou-
gh it did not affect the incidence of cardiovascular 
events83. Such a protective effect was partly due to 
reductions in body weight, HbA1c, and systolic BP. 
No safety concerns regarding kidney-related ad-
verse events were seen83. In a recent meta-analysis 
collating experimental studies in obese CKD pa-
tients, interventions aimed at reducing body wei-
ght showed coherent reductions in blood pressure, 
glomerular hyper-filtration and proteinuria81. A tho-
rough post-hoc analysis of the REIN study showed 
that the nephron-protective effect of ACE inhibition 
in proteinuric CKD patients was maximal in obese 
CKD patients, but minimal in CKD patients with 
normal or low BMI84. Of note, bariatric surgical in-
tervention have been suggested for selected CKD 
and ESRD patients including dialysis patients who 
are waitlisted for kidney transplantation85-87.
Globally, these experimental findings provi-
de a proof of concept for the usefulness of weight 
reduction and ACE inhibition interventions in the 
treatment of CKD in the obese. Studies showing a 
survival benefit of increased BMI in CKD patients, 
however, remain to be explained88. These findings 
limit our ability to make strong recommendations 
about the usefulness and the safety of weight reduc-
tion among individuals with more advanced stages 
of CKD. Lifestyle recommendations to reduce body 
weight in obese people at risk for CKD and in those 
with early CKD appear justified, particularly recom-
mendations for the control of diabetes and hyper-
tension. As the independent effect of obesity control 
on the incidence and progression of CKD is difficult 
to disentangle from the effects of hypertension and 
type 2 diabetes, recommendation of weight loss in 
the minority of metabolically healthy, non-hyper-
tensive obese patients remains unwarranted. These 
considerations suggest that a therapeutic approach 
to overweight and obesity in patients with advanced 
CKD or other significant comorbid conditions has 
to be pursued carefully, with proper considerations 
of the expected benefits and potential complications 
of weight loss over the life span of the individual 
patient.
Conclusions
The worldwide epidemic of obesity affects the 
Earth’s population in many ways. Diseases of the 
kidneys, including CKD, nephrolithiasis and kid-
ney cancers are among the more insidious effects of 
obesity, but which nonetheless have wide ranging 
deleterious consequences, ultimately leading to sig-
nificant excess morbidity and mortality and excess 
costs to individuals and the entire society. 
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Population-wide interventions to control obesity 
could have beneficial effects in preventing the deve-
lopment, or delaying the progression of CKD. It is 
incumbent upon the entire healthcare community to 
devise long-ranging strategies towards improving 
the understanding of the links between obesity and 
kidney diseases, and to determine optimal strategies 
to stem the tide. The 2017 World Kidney Day is an 
important opportunity to increase education and 
awareness to that end. 
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